Literature DB >> 19967470

A case report of gemcitabine treatment for duodenal cancer: the good (a sustained response) and the bad (life threatening refractory thrombotic thrombocytopenic purpura).

Andrew Robinson1, William F Clark.   

Abstract

INTRODUCTION: Adenocarcinoma of the duodenum is a rare cancer and not submitted to the type of clinical trials that guide chemotherapy treatments in other gastrointestinal malignancies. CASE REPORT: This case demonstrates the potential use for gemcitabine, a chemotherapy typically used in pancreas and biliary tract tumors, in this difficult to treat disease as this patient had a partial response to single agent gemcitabine. Unfortunately, this case also demonstrates one of the rare potential adverse reactions to gemcitabine, which is the development of thrombotic thrombocytopenic purpura (TTP).
CONCLUSION: In this case, the TTP was extremely difficult to treat but was resolved with splenectomy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19967470     DOI: 10.1007/s12029-009-9116-5

Source DB:  PubMed          Journal:  J Gastrointest Cancer


  12 in total

Review 1.  Splenectomy for the treatment of thrombotic thrombocytopenic purpura.

Authors:  M C Kappers-Klunne; P Wijermans; R Fijnheer; A J Croockewit; B van der Holt; J T M de Wolf; B Löwenberg; A Brand
Journal:  Br J Haematol       Date:  2005-09       Impact factor: 6.998

2.  The American College of Surgeons Commission on Cancer and the American Cancer Society. Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985-1995.

Authors:  J R Howe; L H Karnell; H R Menck; C Scott-Conner
Journal:  Cancer       Date:  1999-12-15       Impact factor: 6.860

3.  Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases.

Authors:  Paula N Fishman; Gregory R Pond; Malcolm J Moore; Amit Oza; Ronald L Burkes; Lillian L Siu; Ronald Feld; Steven Gallinger; Paul Greig; Jennifer J Knox
Journal:  Am J Clin Oncol       Date:  2006-06       Impact factor: 2.339

4.  Gemcitabine-induced hemolytic uremic syndrome: a case report.

Authors:  T Brodowicz; S Breiteneder; C Wiltschke; C C Zielinski
Journal:  J Natl Cancer Inst       Date:  1997-12-17       Impact factor: 13.506

5.  Outcomes in the treatment of thrombotic thrombocytopenic purpura with splenectomy: a retrospective cohort study.

Authors:  Ubaldo Martinez Outschoorn; Andres Ferber
Journal:  Am J Hematol       Date:  2006-12       Impact factor: 10.047

Review 6.  Current management of thrombotic thrombocytopenic purpura.

Authors:  Johanna A Kremer Hovinga; Sara C Meyer
Journal:  Curr Opin Hematol       Date:  2008-09       Impact factor: 3.284

7.  Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution.

Authors:  S Müller; P Schütt; P Bojko; M R Nowrousian; J Hense; S Seeber; T Moritz
Journal:  Ann Hematol       Date:  2004-09-01       Impact factor: 3.673

8.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Authors:  Christos S Karapetis; Shirin Khambata-Ford; Derek J Jonker; Chris J O'Callaghan; Dongsheng Tu; Niall C Tebbutt; R John Simes; Haji Chalchal; Jeremy D Shapiro; Sonia Robitaille; Timothy J Price; Lois Shepherd; Heather-Jane Au; Christiane Langer; Malcolm J Moore; John R Zalcberg
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

Review 9.  Gemcitabine-associated thrombotic thrombocytopenic purpura.

Authors:  Melanie Zupancic; Prabodh C Shah; Farheen Shah-Khan
Journal:  Lancet Oncol       Date:  2007-07       Impact factor: 41.316

10.  Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide.

Authors:  Gideon Y Stein; Aliza Zeidman; Zinaida Fradin; Meir Varon; Amos Cohen; Moshe Mittelman
Journal:  Int J Hematol       Date:  2004-07       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.